Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren versus ramipril with optional hydrochlorothiazide in essential hypertension
2004-001061-17Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aliskiren, ramipril and hydrochlorothiazide in essential hypertension (2 arms), sponsored by Novartis. Primary endpoint: Change from baseline in mean sitting diastolic blood pressure. Started Feb 2005; status: completed.
02
Drugs
aliskirenramiprilhydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2004-001061-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001061-17.